Baidu
map

NEJM:恩杂鲁胺用于治疗去势耐受性前列腺癌

2020-06-04 MedSci原创 MedSci原创

恩杂鲁胺联合雄激素剥夺治疗可延长非转移性、去势耐受性前列腺癌患者总生存期

初步试验结果显示,对于接受雄激素剥夺治疗的非转移性、去势耐药型前列腺癌患者,恩杂鲁胺显著提高了无转移生存率,并且快速升高了前列腺特异抗原(PSA )水平。 近日研究人员公布了恩杂鲁胺对患者总生存率的影响。
 
在这项随机双盲III期试验中,非转移性、去势耐药前列腺癌的男性在雄激素剥夺治疗基础上,随机接受160毫克恩杂鲁胺或安慰剂,每天一次。研究的主要终点为总生存率。
 
截至2019年10月15日,恩杂鲁胺组933名患者,288名死亡(31%),安慰剂组468名患者中,178名死亡(38%)。 恩杂鲁胺组中位总生存期为67.0个月,安慰剂组为56.3个月 (死亡危险比:0.73)。 恩杂鲁胺组3级或以上不良事件率为17/100患者年,安慰剂组为20/100患者年,最常见的不良事件是疲劳和肌肉骨骼事件。
 
研究认为,恩杂鲁胺联合雄激素剥夺治疗可延长非转移性、去势耐受性前列腺癌患者总生存期。
 
原始出处:
 
Cora N. Sternberg et al. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med, June 4,2020.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2042479, encodeId=ced720424e98d, content=<a href='/topic/show?id=86168035236' target=_blank style='color:#2F92EE;'>#耐受性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80352, encryptionId=86168035236, topicName=耐受性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sun Aug 30 05:32:47 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417712, encodeId=06b0141e712c5, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43843300457, createdName=Smile2681, createdTime=Sat Jun 06 09:32:47 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035295, encodeId=f62d10352959a, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Jun 04 21:32:47 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040756, encodeId=cf451040e5663, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jun 04 21:32:47 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601379, encodeId=242c6013e972, content=<a href='/topic/show?id=32c55286169' target=_blank style='color:#2F92EE;'>#恩杂鲁胺#</a>延长去势耐受前列腺癌生存11个月,还是相当不错吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52861, encryptionId=32c55286169, topicName=恩杂鲁胺)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jun 04 19:21:20 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2042479, encodeId=ced720424e98d, content=<a href='/topic/show?id=86168035236' target=_blank style='color:#2F92EE;'>#耐受性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80352, encryptionId=86168035236, topicName=耐受性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sun Aug 30 05:32:47 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417712, encodeId=06b0141e712c5, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43843300457, createdName=Smile2681, createdTime=Sat Jun 06 09:32:47 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035295, encodeId=f62d10352959a, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Jun 04 21:32:47 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040756, encodeId=cf451040e5663, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jun 04 21:32:47 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601379, encodeId=242c6013e972, content=<a href='/topic/show?id=32c55286169' target=_blank style='color:#2F92EE;'>#恩杂鲁胺#</a>延长去势耐受前列腺癌生存11个月,还是相当不错吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52861, encryptionId=32c55286169, topicName=恩杂鲁胺)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jun 04 19:21:20 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2042479, encodeId=ced720424e98d, content=<a href='/topic/show?id=86168035236' target=_blank style='color:#2F92EE;'>#耐受性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80352, encryptionId=86168035236, topicName=耐受性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sun Aug 30 05:32:47 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417712, encodeId=06b0141e712c5, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43843300457, createdName=Smile2681, createdTime=Sat Jun 06 09:32:47 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035295, encodeId=f62d10352959a, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Jun 04 21:32:47 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040756, encodeId=cf451040e5663, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jun 04 21:32:47 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601379, encodeId=242c6013e972, content=<a href='/topic/show?id=32c55286169' target=_blank style='color:#2F92EE;'>#恩杂鲁胺#</a>延长去势耐受前列腺癌生存11个月,还是相当不错吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52861, encryptionId=32c55286169, topicName=恩杂鲁胺)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jun 04 19:21:20 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
    2020-06-04 旺医

    顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2042479, encodeId=ced720424e98d, content=<a href='/topic/show?id=86168035236' target=_blank style='color:#2F92EE;'>#耐受性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80352, encryptionId=86168035236, topicName=耐受性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sun Aug 30 05:32:47 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417712, encodeId=06b0141e712c5, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43843300457, createdName=Smile2681, createdTime=Sat Jun 06 09:32:47 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035295, encodeId=f62d10352959a, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Jun 04 21:32:47 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040756, encodeId=cf451040e5663, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jun 04 21:32:47 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601379, encodeId=242c6013e972, content=<a href='/topic/show?id=32c55286169' target=_blank style='color:#2F92EE;'>#恩杂鲁胺#</a>延长去势耐受前列腺癌生存11个月,还是相当不错吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52861, encryptionId=32c55286169, topicName=恩杂鲁胺)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jun 04 19:21:20 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
    2020-06-04 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2042479, encodeId=ced720424e98d, content=<a href='/topic/show?id=86168035236' target=_blank style='color:#2F92EE;'>#耐受性前列腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80352, encryptionId=86168035236, topicName=耐受性前列腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=9fe6351, createdName=flyingeagle77, createdTime=Sun Aug 30 05:32:47 CST 2020, time=2020-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1417712, encodeId=06b0141e712c5, content=<a href='/topic/show?id=aada80351ae' target=_blank style='color:#2F92EE;'>#耐受性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80351, encryptionId=aada80351ae, topicName=耐受性)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=43843300457, createdName=Smile2681, createdTime=Sat Jun 06 09:32:47 CST 2020, time=2020-06-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1035295, encodeId=f62d10352959a, content=顶刊就是顶刊,谢谢梅斯带来这么高水平的研究报道,我们科里同事经常看梅斯,分享梅斯上的信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=旺医, createdTime=Thu Jun 04 21:32:47 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040756, encodeId=cf451040e5663, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Thu Jun 04 21:32:47 CST 2020, time=2020-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=601379, encodeId=242c6013e972, content=<a href='/topic/show?id=32c55286169' target=_blank style='color:#2F92EE;'>#恩杂鲁胺#</a>延长去势耐受前列腺癌生存11个月,还是相当不错吧, beContent=null, objectType=article, channel=null, level=null, likeNumber=175, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52861, encryptionId=32c55286169, topicName=恩杂鲁胺)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=lovetcm, createdTime=Thu Jun 04 19:21:20 CST 2020, time=2020-06-04, status=1, ipAttribution=)]
    2020-06-04 lovetcm

    #恩杂鲁胺#延长去势耐受前列腺癌生存11个月,还是相当不错吧

    0

相关资讯

Cancer Res:IRF8与AR负反馈调节回路的缺失能够促进前列腺生长和恩杂鲁胺抗性

在不可治愈的去势抵抗性前列腺癌(CPRC)中,对新的雄激素受体(AR)拮抗剂恩杂鲁胺(ENZ)的抗性是有AR的过表达驱使的。

JAMA Oncol:恩杂鲁胺治疗去势抵抗性前列腺癌男性中新的未确认骨病变与治疗结果相关性研究

对恩杂鲁胺响应的转移去势抵抗性前列腺癌(mCRPC)男性,在治疗后的扫描造影中检测到的新的未确认的骨病变可能表示着愈合的成骨反应,同时也称为假性进展,该情况能够导致治疗的提前终止。最近,有研究人员在恩杂鲁胺治疗的mCPRC男性中确认了跟踪调查期间扫描检测到的新的未确认病变和治疗结果之间的相关性。在PREVAIL的643名男性中(平均年龄,72(43-93)岁),177名具有稳定的疾病或者对恩杂鲁胺

恩杂鲁胺Xtandi获FDA批准用于治疗转移性去势敏感性前列腺癌

辉瑞和Astellas宣布,美国食品和药物管理局(FDA)已批准其联合开发药物Xtandi(恩杂鲁胺,enzalutamide)的补充新药申请(sNDA)。

Zydus Cadila推出恩杂鲁胺液体胶囊Obnyx,将使该前列腺癌疗法的价格降低2/3

Obnyx的推出可将治疗费用显着降低近70%,其每周治疗费用为5995卢比,每月治疗费用低于27000卢比。

Prostate Cancer P D:镭-223和恩杂鲁胺或阿比特龙/强的松同时或分层治疗转移去势抵抗性前列腺癌

最近,有研究人员评估了镭-223联用阿比特龙/强的松或恩杂鲁胺的真实世界数据。之前的ERA223试验(NCT0203678)阐释了镭-223联用阿比特龙和强的松/泼尼松龙能够增加转移去势抵抗性前列腺癌

Prostate Cancer P D:去势抵抗性前列腺癌中阿比特龙和恩杂鲁胺的序贯治疗分析

最近,有研究人员进行了系统的回顾和元分析评估了阿比特龙(ABI)和恩杂鲁胺(ENZ)的序贯治疗在去势抵抗性前列腺癌(CRPC)患者中的预后价值。

Baidu
map
Baidu
map
Baidu
map